- Home
- OTLK vs AIIO Comparison
OTLK vs AIIO Comparison
Compare OTLK & AIIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | AIIO |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United Arab Emirates |
| Employees | N/A | 68 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Auto Manufacturing |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 32.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | AIIO |
|---|---|---|
| Price | $0.31 | $0.63 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 1.4M |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.07 |
| 52 Week High | $3.39 | $2.82 |
Technical Indicators
Market Signals| Indicator | OTLK | AIIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 60.24 |
| Support Level | $0.17 | $0.56 |
| Resistance Level | $0.46 | $0.73 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 62.21 | 21.48 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.